7 Growth Stocks To Buy In 2025 – 10x Wealth Report

getty

If increasing net worth is on your list of 2025 resolutions, re-evaluating your growth stock portfolio may be the first action item. You can fill the gaps with companies that have proven growth track records and strong outlooks. Seven promising stocks to consider are introduced below.

Methodology Used For These Growth Stock Picks

Growth stocks are equity shares likely to outperform their peers and the broader market. Outperformance can happen when a company successfully delivers an innovative solution to a sizable audience.

Companies that unlock this growth puzzle tend to keep doing it. To be clear, past growth performance does not guarantee future success. But it does show a leadership team’s ability to see big opportunities, implement solutions and create value.

For that reason, my screening criteria for growth stocks includes historic growth metrics and future performance expectations:

Revenue growth for 5 or more consecutive years
5-year revenue growth outlook of 15% or more
Trailing 12-month (TTM) revenue growth of 10% or more
Expected EPS growth this year of 10% or more
5-year EPS growth outlook of 20% or more
ROE of 10% or more
Buy or strong buy ratings from analysts

Much more than breaking news, our diverse reporting digs deeper with unparalleled insights that empower you to make better informed decisions. Become a Forbes member and get unlimited access to cutting-edge strategies, actionable insights, and updated analysis from our network of leading finance experts. Unlock Premium Access — Free For 25 Days.

The table below shows seven top growth stocks that meet the above parameters.

Table data source: Stockanalysis.com.

Let’s take a closer look at each of these fast-growing companies. Data comes from company reports and Stockanalysis.com.

1. Eli Lilly (LLY)

Share Price: $757.78
Years of revenue growth: 6
Trailing 12-month revenue growth: 27.4%
5-year revenue growth outlook: 19.2%
Expected EPS growth this year: 129.7%
5-year EPS growth outlook: 41.0%
ROE: 65.3%
Analyst rating: Strong Buy

Eli Lilly Business Overview

Eli Lilly is a drugmaker offering treatments for diabetes, weight loss, plaque psoriasis, anxiety, fibromyalgia and other conditions.

Why LLY Is A Top Choice

Eli Lilly has business momentum, thanks to Mounjaro and Zepbound, two formulations that treat diabetes and obesity, respectively. Both drugs are versions of the compound tirzepatide, a GLP-1 receptor agonist.

GLP-1 drugs have been popular since competing product Ozempic became the weight-loss answer for Hollywood A-listers. Ozempic is technically a diabetes medication, but its maker Novo Nordisk markets a related product called Wegovy for weight loss. Demand for Ozempic, Wegovy and the Eli Lilly treatments have outpaced supply, causing shortages in the U.S.

Lilly is addressing the shortage by investing billions in production capacity. The company has also completed clinical trials showing its Zepbound treatment is more effective for weight loss than Wegovy.

Since 2020, LLY’s EPS has varied from $5.80 to $6.90. Analysts expect 2024 and 2025 EPS of $13.32 and $22.24, respectively.

2. ServiceNow (NOW)

Share Price: $1,078.73
Years of revenue growth: 14
TTM revenue growth: 23.5%
5-year revenue growth outlook: 19.9%
Expected EPS growth this year: 67%
5-year EPS growth outlook: 26.8%
ROE: 16.2%
Analyst rating: Buy

ServiceNow Business Overview

ServiceNow offers a workflow automation platform for enterprise technology management. The platform is sold on a subscription basis to Fortune 500 companies and others.

Why NOW Is A Top Choice

In the third quarter of 2024, ServiceNow had subscription growth of 22.5%—beating the high end of the company’s guidance. Customers are responding well to ServiceNow’s AI-focused messaging. The company is positioning its Now platform as an essential AI-powered resource for digital transformation.

The company’s investments in efficiency-enhancing generative AI features are also paying off. Examples include industry-targeted AI solutions for financial services, telecommunications and more. ServiceNow is also incorporating agenic AI into its platform. Agenic AI is an emerging AI innovation that can complete complex tasks, learn and make decisions without human intervention.

Analysts expect NOW to produce 2024 and 2025 EPS of $14.06 and $16.87, respectively. The company delivered $8.42 in EPS in 2023 and $1.60 in 2022.

3. Shopify (SHOP)

Share Price: $107.57
Years of revenue growth: 11
TTM revenue growth: 23.5%
5-year revenue growth outlook: 21.5%
Expected EPS growth this year: 1156.1%
5-year EPS growth outlook: 79%
ROE: 15.0%
Analyst rating: Buy

Shopify Business Overview

Shopify manages and sells a commerce platform that customers use to manage inventory and sell products online and offline.

Why SHOP Is A Top Choice

Shopify generates about $8 billion in annual revenue with a leading 28% market share in the e-commerce platform segment.

Like ServiceNow, Shopify invests continually in platform features to enhance efficiency and productivity for customers. In Shopify’s case, the customers range from solo entrepreneurs to big brands. Recent enhancements include the launch of generative AI to respond to customer queries and the expansion of sales tax management to the entire EU.

The company has a great growth track record, expanding sales from $1.5 billion in 2019 to $7 billion last year. Analysts expect EPS of $1.29 in 2024 and $1.54 in 2025, both sizable upticks from the $0.10 earned in 2023.

Discover more in-depth insights, entrepreneurial advice and winning strategies that can propel your journey forward and save you from making costly mistakes. Elevate your journey by becoming a Forbes member. Unlock Premium Access — Free For 25 Days.

4. MercadoLibre (MELI)

Share Price: $1,673.67
Years of revenue growth: 19
TTM revenue growth: 35%
5-year revenue growth outlook: 21.7%
Expected EPS growth this year: 85.4%
5-year EPS growth outlook: 36.5%
ROE: 42.6%
Analyst rating: Strong Buy

MercadoLibre Business Overview

MercadoLibre manages the top e-commerce marketplace and one of the largest online payment platforms in Latin America.

Why MELI Is A Top Choice

MELI is often called the “Amazon of South America.” Both companies operate dominant e-commerce marketplaces in their regions and have delivered strong returns to shareholders for a decade. MercadoLibre does not have a cloud computing business like Amazon, but it does have a popular digital payment solution, Mercado Pago.

Between 2019 and 2023, MercadoLibre grew annual revenues from $2.2 billion to more than $14.4 billion. The bottom line increased from a $3.71 loss per share to earnings of $19.47 per share, with steady operating margin growth along the way.

Analysts expect the growth pattern to continue. Strengthening economic conditions in Argentina is one reason for optimism. MercadoLibre has a strong position there in e-commerce and payments, with no formidable competitors. The 2024 and 2025 EPS predictions for MELI are $36.10 and $47.92, respectively.

5. Monolithic Power Systems (MPWR)

Share Price: $592.84
Years of revenue growth: 12
TTM revenue growth: 11.6%
5-year revenue growth outlook: 17.1%
Expected EPS growth this year: 63.8%
5-year EPS growth outlook: 25%
ROE: 20.2%
Analyst rating: Strong Buy

Monolithic Power Systems Business Overview

Monolithic Power Systems designs and sells power circuits that control voltage to servers, AI and storage applications, vehicle components, home appliances, communications infrastructure and more.

Why MPWR Is A Top Choice

Monolithic has revenue exposure to three transforming industries: automotive, AI and 5G. This positioning helped the company raise its stock price from about $384 in 2021 to a high of $940 last October.

However, the MPWR stock price has since dipped to the $590s. The prompt was a report speculating that Nvidia canceled its backlogged orders of a Monolithic product due to performance issues. Monolithic denied the speculations, but investors have not been convinced.

The pullback may create an opportunity to buy this growing company. A Citi analyst thinks so. Analyst Kelsey Chia initiated coverage on MPWR with a buy rating and a price target of $700. Chia cited strength in AI and automotive, arguing that the opportunity available will outweigh any market share loss for Monolithic with Nvidia.

Analysts expect MPWR to produce 2024 EPS of $14.35, up from $8.76 in the prior year. The 2025 EPS outlook is $16.89.

6. Shift4 Payments (FOUR)

Share Price: $101.86
Years of revenue growth: 5
TTM revenue growth: 31.4%
5-year revenue growth outlook: 23.3%
Expected EPS growth this year: 163.3%
5-year EPS growth outlook: 36.2%
ROE: 22%
Analyst rating: Buy

Shift4 Payments Business Overview

Shift4 Payments provides integrated payment processing solutions to merchants in the U.S. and internationally.

Why FOUR Is A Top Choice

Shift4 Payments has steadily grown sales from $731 million in 2019 to more than $3 billion in the 12 months before September 30, 2024. In the third quarter of 2024, the company produced record cash flow, signed new hospitality and gaming customers, expanded geographically and raised its full-year sales and Ebitda outlooks.

With strong sales, a $33 billion backlog and three acquisitions to integrate, Shift4 Payments has momentum. Acquisitions of POS companies Revel and Vectron expand the company’s network of merchant customers, driving revenue and creating cross-sell opportunities.

Those are a few reasons why analysts believe FOUR will produce EPS of $3.75 in 2024 and $4.71 in 2025—marking significant earnings improvement from $1.42 in 2023.

7. Corcept Therapeutics (CORT)

Share Price: $51.56
Years of revenue growth: 11
TTM revenue growth: 39.7%
5-year revenue growth outlook: 24.8%
Expected EPS growth this year: 47.6%
5-year EPS growth outlook: 41.1%
ROE: 25.8%
Analyst rating: Strong Buy

Corcept Therapeutics Business Overview

Corcept Therapeutics develops treatments for metabolic, psychiatric and oncologic disorders. The company has one marketed product, a cortisol receptor blocker called Korlym. Corcept’s pipeline includes Phase III and Phase IV treatments for Cushing’s Syndrome and a Phase III treatment for ovarian cancer, among other things.

Why CORT Is A Top Choice

Korlym has produced steadily growing revenue since 2019—including 48% revenue growth and 46% diluted net income per share growth in the third quarter of 2024.

Conditions look good for the growth to continue. The company recently announced positive results from the treatment phase of its Catalyst study: Korlym reached its primary endpoint in patients with Cushing’s Syndrome and hard-to-control type 2 diabetes. An earlier phase of Catalyst showed Cushing’s is more common than previously thought.

Corcept has also seen positive clinical trial results from a Phase III study of relacorilant, another treatment for Cushing’s Syndrome.

The EPS expectation for Corcept in 2024 is $1.39, which compares favorably to 2023 EPS of $0.94. For 2025, analysts believe the company will produce EPS of $1.79.

Bottom Line

You can wish for a prosperous new year, but strategic actions may get you there quicker. Start by reviewing your growth stock portfolio and replacing the duds with companies poised to shine in 2025.